top of page

on the pen doesn't exist without your


I'm Dave. On The Pen is my thing. My passion. But so are my 4 kids, and so is my day job. In order to sustain my efforts, I have to cover the costs involved with OTP. The website, the programs that make it pretty, and the tools that help people connect to it. A gift of ANY amount is greatly appreciated!

Untitled design (4).png

Generic Versions of Zepbound: How Recent News Affects Their Future

As the popularity of incretin mimetic peptides increase, compounded and generic verisions of tirzepatide (Mounjaro and Zepbound) are under increased scrutiny. Recent developments reveal a complex interplay of regulatory pressures, legal strategies, and media narratives, raising important questions about the future accessibility of these essential drugs.

Regulatory Pressures and Compounded Medications

Compounded medications have long been a vital part of healthcare, particularly those produced by 503b pharmacies. These specialized facilities, established by legislation in 2013, are licensed to mass-produce drugs during shortages, ensuring patients have access when standard supplies are insufficient. However, recent litigation has put a spotlight on the origins of these medications, potentially challenging the role of 503b pharmacies in the broader pharmaceutical ecosystem.

Eli Lilly’s Legal Strategy

Eli Lilly, the manufacturer and patent holder of tirzepatide , has begun aggressively protecting its interests by challenging non-branded versions. The company is specifically targeting research-grade suppliers, aiming to limit competition and maintain control over its products. Some have theorized that research purpose only peptide companies (selling peptides without prescriptions “not for human consumption”) share the same source API manufacturers as the 503A pharmacies selling “compound tirzepatide” with a prescription. If true, the danger would be that there is potential to choke off the API source for legitimate compounding pharmacies. This new legal strategy from Lilly reflects a broader trend among pharmaceutical giants to safeguard their market share, raising concerns about the future availability of compounded/generic GLP-1 medications.


The Influence of Media Narratives

While the API manufacturers of tirzepatide are being hit with cease and desist letters, speculation also abounds that large pharmaceutical companies are influencing media narratives to undermine trust in compounded versions of incretin mimetics. By shaping public perception, these companies aim to sway opinion against compounded medications, framing them as inferior or unsafe alternatives. This tactic, if true, highlights the significant power dynamics at play in the pharmaceutical industry, where media influence can shape consumer trust and policy discussions.

The Role of 503a / 503b Pharmacies

503b pharmacies are outsourcing facilities that can mass-produce compounded medications in bulk for healthcare facilities without patient-specific prescriptions, focusing on drugs during shortages. In contrast, 503a pharmacies are traditional compounding pharmacies that create medications tailored to individual patient prescriptions. We did a more in depth look at the differences between the two in April

Despite recent attempts to undermine public confidence, 503b pharmacies (a list can be found here) remain a cornerstone in the production and accessibility of medications that are in shortage. Their legal mandate to address drug shortages positions them as essential players in the healthcare landscape. Entirely new legislation would be required to halt their operations, and despite the attempts by big pharma to intervene, the current regulatory environment suggests that compounded medications will continue to play a critical role in patient care and access.

Future Outlook: Compounded Medications and Accessibility

The strategic battle between pharmaceutical companies and compounded drug suppliers has significant implications for patient access to medications. While compounded versions may face regulatory and legal challenges, their necessity in addressing drug shortages underscores their importance in the healthcare system. The future may hold further debates and regulatory scrutiny, but compounded medications are unlikely to disappear entirely.

Our Continued Commitment to Advocacy and Education

As we navigate these regulatory and industry dynamics, it’s crucial to stay informed about the developments impacting compounded medications. The balance between ensuring drug safety and maintaining accessibility remains delicate. Compounded medications, supported by the framework established for 503a and 503b pharmacies, are positioned to remain a vital part of our healthcare system despite ongoing challenges. We should continue to advocate that that framework exist, and altered only to improve patient safety and accessibility.

Stay tuned to for more updates and in-depth analysis on the latest developments in weight loss and diabetes treatments. Sharing this article is a powerful form of advocacy that brings us closer to our goal of educating the masses and reducing the stigma of obesity. If you found this article insightful, please share it within your networks, especially in Facebook groups and Reddit forums dedicated to GLP-1 medications and diabetes management. Together, we can make a difference.

1 Comment

Dave, I would like to see you contact Alison at She is an expert on what is happening and involved with Scott Bruner and the compounders. I know she would be willing to fill your ears with what is going on. Good Luck, Deborah

bottom of page